AstraZeneca today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. has now received formal marketing authorisation from the National Medical Products Administration for roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor and new oral treatment for patients with anaemia caused by chronic kidney disease that are on dialysis.
AstraZeneca today announced a new collaboration with Cancer Research UK to launch a centre of excellence in genetic screening, cancer modelling and big data processing aimed at accelerating the discovery of new cancer medicines.
AstraZeneca and MedImmune today announced overall survival results for the Phase III EAGLE trial. EAGLE is a randomised, open-label, multi-centre trial evaluating Imfinzi monotherapy or Imfinzi in combination with tremelimumab versus standard-of-care chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma......
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, have presented new, long-term follow-up results for Calquence (acalabrutinib) in patients with relapsed or refractory mantle cell lymphoma (MCL).
NT-rådets (Rådet för nya terapier) rekommendation till landstingen är att Imfinzi (durvalumab) kan införas som ett behandlingsalternativ vid icke småcellig lungcancer (NSCLC). Beslutet innebär att NT rådet ser ett visst värde i behandlingsalternativet men låter landsting och regioner själva avgöra i vilken mån det ska införas som ett behandlingsalternativ.
AstraZeneca, together with Acerta Pharma, its haematology research and development centre of excellence, and MedImmune, its global biologics research and development arm, will present 27 abstracts, including six oral presentations, at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, USA, December 1-4.
AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation for Fasenra (benralizumab) for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA).
AstraZeneca and MedImmune, today announced final overall survival results for the Phase III MYSTIC trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) monotherapy and the combination of Imfinzi and tremelimumab, an anti-CTLA4 antibody, versus standard-of-care platinum-based chemotherapy in previously-untreated patients with Stage IV (metastatic)NSCLC.
AstraZeneca has agreed to sell US rights to Synagis(palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orphan Biovitrum AB (publ) (Sobi). Sobi will commercialise Synagis in the US and around 130 AstraZeneca employees will transfer to Sobi as part of the transaction.
Behandling av typ 2-diabetes med dapagliflozin (Forxiga) i en bred patientpopulation, minskar risken för sjukhusinläggningar på grund av hjärtsvikt eller hjärtrelaterad död med 17 procent jämfört med placebo (4,9% jämfört med 5,8%). Samtidigt bekräftas den sedan tidigare kända säkerhetsprofilen för dapagliflozin. Det visar de första resultaten från en stor internationell kardiovaskulär fas III-stu
AstraZeneca and Merck & Co., Inc. US today announced that the US FDA has accepted a supplemental New Drug Application for Priority Review for the use of Lynparza tablets as a maintenance treatment in patients with newly-diagnosed, BRCA-mutated (BRCAm) advanced ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.
Fewer MACE events observed with Farxiga vs. placebo, but this finding did not reach statistical significance No imbalance in amputations, fractures, bladder cancer or Fournier’s gangrene with Farxiga vs. placebo
AstraZeneca återgår till tillväxt i produktförsäljningen; nya läkemedel och tillväxtmarknaderna leder vägen
AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), usedfor the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis. The rights cover markets outside the US and the US royalties for the medicines.
AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III CV outcomes trial (CVOT) DECLARE-TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company’s CVRM therapy area at the American Heart Association (AHA) Scientific Sessions, 10-12 November 2018, in Chicago, Illinois, USA.
AstraZeneca has agreed to divest the prescription medicine rights to Nexium(esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal. The medicines are outside AstraZeneca’s three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory
AstraZeneca today presented the results from the HARMONIZE Global Phase III trial, which investigated the safety and efficacy of Lokelma (sodium zirconium cyclosilicate) vs. placebo in patients with hyperkalaemia in Japan, Korea, Taiwan and Russia. The results were presented at the American Society of Nephrology (ASN) Kidney Week 2018, San Diego, California, US.
AstraZeneca, and its global biologics research and development arm MedImmune, today announced a new multi-term agreement with Innate Pharma (Innate), building on an existing collaboration, aimed at accelerating each company’s oncology portfolio and bringing new medicines to patients more quickly.
AstraZeneca will present new research spanning the Company’s Cardiovascular, Renal and Metabolism (CVRM) therapy area at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in San Diego, US, 23-28 October 2018.
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today announced detailed results from the Phase III SOLO-1 trial testing Lynparza (olaparib) tablets as a maintenance treatment for patients with newly-diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.